BRISTOL MYERS SQUIBB CO (BMY) — Investment Memo

🐂 The Bull Case (Warren's voice)

• Durable cash flow machine – FCF of $12.8B in 2025 is real, not accounting noise. Even if Eliquis falls, the base business generates ~$8B in FCF from Opdivo, Eliquis (temporarily), and growth brands like Breyanzi (+25% YoY). That's a 10%+ FCF yield at the current ~$50B market cap.
• Pipeline optionality – $9.8B R&D spend (20% of revenue) funds a deep pipeline: CAR-T, cell therapy, immunology. One surprise blockbuster – say an oral Eliquis replacement or next-gen Opdivo combo – could refill the patent gap. Not likely, but possible.
• Price to be a buyer – At $225.96/share DCF fair value (15% FCF growth, 10% discount), the stock today trades at ~$25 (roughly $52B market cap). That's a 90% discount to intrinsic value if the DCF assumptions hold. Even with halved FCF, intrinsic value is ~$110/share – a 4× upside from here. Buffett would say: "If the business survives, the price is absurdly low."
• Restructuring savings are real – $2B in annual cost cuts flow straight to FCF. The 2025 margin compression is temporary; legacy drag flattens after 2028.

🐻 The Bear Case (Charlie inverts)

Munger's rule: "Show me where I'll die and I won't go there."

• Scenario 1: The Eliquis cliff (2028–2029) – $12.3B in revenue (25% of total) vaporizes. No pipeline drug comes close. FCF drops from $12.8B to ~$6B – after interest and R&D, net income turns negative. Debt of $44.8B becomes unserviceable. Bankruptcy is unlikely, but a forced equity raise at distressed prices is the permanent impairment.
• Scenario 2: The acquisition hangover – $80B in goodwill sits on the balance sheet (8× tangible equity). If the FDA rejects a key pipeline drug (e.g., Karuna's schizophrenia candidate or a CAR-T setback), another $10–20B impairment wipes out equity. The $9.8B equity base evaporates – no cushion. This is not "recession risk"; it's structural balance sheet fragility.
• Most likely permanent impairment – The combination: Eliquis cliff + one pipeline failure + no buyback discipline. Earnings fall 60% by 2030, ROE collapses to single digits, and the stock trades at book value (~$5/share). Management keeps acquiring to "fill the hole", compounding the destruction.

💰 Valuation & Margin of Safety

• DCF intrinsic value estimate: $225.96/share (15% FCF growth, 10% discount, 3% terminal). We reject this as fantasy. The growth assumption ignores the Eliquis cliff. A realistic DCF: 5% FCF decline for 5 years, then 3% growth → intrinsic value ~$55/share.
• 25% margin of safety entry: $41/share (conservative buyer).
• 50% margin of safety entry: $28/share (Buffett's ideal – buys only when he's "willing to lose half").
• Current price: ~$25/share (market cap ~$52B). This is already below our conservative intrinsic. But fair price requires structural improvement that management has not delivered.

Is it cheap? Yes, based on current FCF. But it's a value trap – cheap for a reason. The patent cliff is a known unknown that wipes out earnings. The price may fall another 50% as the cliff approaches.

Verdict: PASS

The business generates real cash today, but the Eliquis patent cliff is a visible 100-foot drop, and management has shown no ability to fill the hole – only a talent for overpaying for acquisitions. At $25/share, the market is pricing in the cliff, but the balance sheet leverage and pipeline uncertainty mean the downside is still catastrophic. We need a 50% margin of safety on a realistic intrinsic value of $55/share – that would be $28/share – and even then, we'd only buy after seeing actual pipeline data that justifies the survival.